UPA Labs | Hybrid Research Peptide 33mg (Magtidelira 33) | Compound Peptide Pen

Advanced Multi-Pathway Metabolic Research Compound

UPA Magtidelira 33 is an investigational hybrid peptide research compound studied for its multi-pathway activity across metabolic signalling systems, widely referenced in laboratory research exploring glucose regulation, appetite modulation, and energy homeostasis mechanisms.

This type of hybrid peptide formulation is commonly investigated in scientific models focused on endocrine communication, insulin response pathways, and multi-receptor metabolic interactions within controlled experimental environments.

Developed as a 33mg compound peptide pen, this formulation is designed for laboratory preparation and controlled research applications where combined metabolic signalling and peptide interaction studies are of scientific interest.

UPA Magtidelira 33 Hybrid Peptide Research Compound Pen (33mg)

• Hybrid peptide research compound studied in metabolic signalling models
• Investigated in glucose regulation and insulin response research
• Of interest in appetite modulation and energy balance pathway studies
• Explored in multi-receptor endocrine communication research environments
• 33mg pen format designed for laboratory preparation use
• High-purity investigational formulation from UPA
• Manufactured for stability, consistency, and research reliability
• Strictly intended for laboratory research use only

⚖️ DISCLAIMER

This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPHRA) for human or animal use.

This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.

Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.